Novartis Gene Therapies

ZOLGENSMA

Manufacturer:

Novartis Gene Therapies

Zolgensma HCPCS:

J3399

HCPCS Code Descriptor:

Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes

Category:

J Code

Zolgensma NDCs:

71894-0120-02, 71894-0139-09, 71894-0140-09, 71894-0121-03, 71894-0124-04, 71894-0125-04, 71894-0123-03, 71894-0126-04, 71894-0127-05, 71894-0122-03, 71894-0128-05, 71894-0130-06, 71894-0131-06, 71894-0132-06, 71894-0133-07, 71894-0129-05, 71894-0134-07, 71894-0135-07, 71894-0138-08, 71894-0137-08, 71894-0136-08, 71894-0141-09

Primary Type:

Genetic Disorder

Generic/Specialty Status:

Single-Source

Package Type:

Kit

Route of Administration:

Intravenous

Zolgensma CPT Codes:

Potential CPT administration codes for Zolgensma can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

71894-0120-02, 71894-0139-09, 71894-0140-09, 71894-0121-03, 71894-0124-04, 71894-0125-04, 71894-0123-03, 71894-0126-04, 71894-0127-05, 71894-0122-03, 71894-0128-05, 71894-0130-06, 71894-0131-06, 71894-0132-06, 71894-0133-07, 71894-0129-05, 71894-0134-07, 71894-0135-07, 71894-0138-08, 71894-0137-08, 71894-0136-08, 71894-0141-09

About Zolgensma:

ZOLGENSMA is a Genetic Disorder drug manufactured by Novartis Gene Therapies and administered via the Intravenous route of administration. The J Code: J3399 is aligned to the drug ZOLGENSMA.

ZOLGENSMA is an adeno-associated virus vector-based gene therapy commonly used to treat spinal muscular atrophy. It is indicated for use in patients with bi-allelic mutations in the SMN1 gene. ZOLGENSMA (J3399) works by loading the recombinant adenovirus vector with a functional copy of the gene that encodes the human SMN protein. It is commonly used in patients under the age of 2.

ACCESS PRICING AND MORE BY REGISTERING

J3399 Added Date:

July 1, 2020

J3399 Effective Date:

July 1, 2020

J3399 Termination Date:

HCPCS Active

Zolgensma billing and coding information can be found through Novartis Gene Therapies at the link below:
Zolgensma patient assistance information can be found through Novartis Patient Support at the URL: https://www.zolgensma.com/onegene-program
Our team is still working to identify a prescribing information source for ZOLGENSMA
Our team has not yet identified a source of side effects information for ZOLGENSMA. Please check back in a few weeks.